Eintrag weiter verarbeiten
Management of immune checkpoint inhibitor‐related rheumatic adverse events
Gespeichert in:
| Zeitschriftentitel: | Thoracic Cancer |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Thoracic Cancer, 11, 2020, 1, S. 198-202 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Zhou, Jiaxin Wang, Hanping Guo, Xiaoxiao Wang, Qian Duan, Lian Si, Xiaoyan Zhang, Li Liu, Xiaowei Li, Yue Zhang, Wen Zhang, Li Zhou, Jiaxin Wang, Hanping Guo, Xiaoxiao Wang, Qian Duan, Lian Si, Xiaoyan Zhang, Li Liu, Xiaowei Li, Yue Zhang, Wen Zhang, Li |
|---|---|
| author |
Zhou, Jiaxin Wang, Hanping Guo, Xiaoxiao Wang, Qian Duan, Lian Si, Xiaoyan Zhang, Li Liu, Xiaowei Li, Yue Zhang, Wen Zhang, Li |
| spellingShingle |
Zhou, Jiaxin Wang, Hanping Guo, Xiaoxiao Wang, Qian Duan, Lian Si, Xiaoyan Zhang, Li Liu, Xiaowei Li, Yue Zhang, Wen Zhang, Li Thoracic Cancer Management of immune checkpoint inhibitor‐related rheumatic adverse events Pulmonary and Respiratory Medicine Oncology General Medicine |
| author_sort |
zhou, jiaxin |
| spelling |
Zhou, Jiaxin Wang, Hanping Guo, Xiaoxiao Wang, Qian Duan, Lian Si, Xiaoyan Zhang, Li Liu, Xiaowei Li, Yue Zhang, Wen Zhang, Li 1759-7706 1759-7714 Wiley Pulmonary and Respiratory Medicine Oncology General Medicine http://dx.doi.org/10.1111/1759-7714.13249 <jats:p>Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wide use of ICIs is associated with a spectrum of immune‐related adverse events (irAEs) that can affect any organ system, and may sometimes be life threatening. Rheumatic irAEs are not an infrequent type of irAE. In this systematic review, we consider the clinical characteristics of rheumatic irAEs, including patients with pre‐existing rheumatic diseases, and focus on the management of rheumatic irAEs.</jats:p> Management of immune checkpoint inhibitor‐related rheumatic adverse events Thoracic Cancer |
| doi_str_mv |
10.1111/1759-7714.13249 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS8xNzU5LTc3MTQuMTMyNDk |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS8xNzU5LTc3MTQuMTMyNDk |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Wiley, 2020 |
| imprint_str_mv |
Wiley, 2020 |
| issn |
1759-7714 1759-7706 |
| issn_str_mv |
1759-7714 1759-7706 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
zhou2020managementofimmunecheckpointinhibitorrelatedrheumaticadverseevents |
| publishDateSort |
2020 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Thoracic Cancer |
| source_id |
49 |
| title |
Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_unstemmed |
Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_full |
Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_fullStr |
Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_full_unstemmed |
Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_short |
Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_sort |
management of immune checkpoint inhibitor‐related rheumatic adverse events |
| topic |
Pulmonary and Respiratory Medicine Oncology General Medicine |
| url |
http://dx.doi.org/10.1111/1759-7714.13249 |
| publishDate |
2020 |
| physical |
198-202 |
| description |
<jats:p>Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wide use of ICIs is associated with a spectrum of immune‐related adverse events (irAEs) that can affect any organ system, and may sometimes be life threatening. Rheumatic irAEs are not an infrequent type of irAE. In this systematic review, we consider the clinical characteristics of rheumatic irAEs, including patients with pre‐existing rheumatic diseases, and focus on the management of rheumatic irAEs.</jats:p> |
| container_issue |
1 |
| container_start_page |
198 |
| container_title |
Thoracic Cancer |
| container_volume |
11 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792333591830593549 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:14:48.553Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Management+of+immune+checkpoint+inhibitor%E2%80%90related+rheumatic+adverse+events&rft.date=2020-01-01&genre=article&issn=1759-7714&volume=11&issue=1&spage=198&epage=202&pages=198-202&jtitle=Thoracic+Cancer&atitle=Management+of+immune+checkpoint+inhibitor%E2%80%90related+rheumatic+adverse+events&aulast=Zhang&aufirst=Li&rft_id=info%3Adoi%2F10.1111%2F1759-7714.13249&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792333591830593549 |
| author | Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Zhang, Wen, Zhang, Li |
| author_facet | Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Zhang, Wen, Zhang, Li, Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Zhang, Wen, Zhang, Li |
| author_sort | zhou, jiaxin |
| container_issue | 1 |
| container_start_page | 198 |
| container_title | Thoracic Cancer |
| container_volume | 11 |
| description | <jats:p>Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wide use of ICIs is associated with a spectrum of immune‐related adverse events (irAEs) that can affect any organ system, and may sometimes be life threatening. Rheumatic irAEs are not an infrequent type of irAE. In this systematic review, we consider the clinical characteristics of rheumatic irAEs, including patients with pre‐existing rheumatic diseases, and focus on the management of rheumatic irAEs.</jats:p> |
| doi_str_mv | 10.1111/1759-7714.13249 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS8xNzU5LTc3MTQuMTMyNDk |
| imprint | Wiley, 2020 |
| imprint_str_mv | Wiley, 2020 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275 |
| issn | 1759-7714, 1759-7706 |
| issn_str_mv | 1759-7714, 1759-7706 |
| language | English |
| last_indexed | 2024-03-01T14:14:48.553Z |
| match_str | zhou2020managementofimmunecheckpointinhibitorrelatedrheumaticadverseevents |
| mega_collection | Wiley (CrossRef) |
| physical | 198-202 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Thoracic Cancer |
| source_id | 49 |
| spelling | Zhou, Jiaxin Wang, Hanping Guo, Xiaoxiao Wang, Qian Duan, Lian Si, Xiaoyan Zhang, Li Liu, Xiaowei Li, Yue Zhang, Wen Zhang, Li 1759-7706 1759-7714 Wiley Pulmonary and Respiratory Medicine Oncology General Medicine http://dx.doi.org/10.1111/1759-7714.13249 <jats:p>Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wide use of ICIs is associated with a spectrum of immune‐related adverse events (irAEs) that can affect any organ system, and may sometimes be life threatening. Rheumatic irAEs are not an infrequent type of irAE. In this systematic review, we consider the clinical characteristics of rheumatic irAEs, including patients with pre‐existing rheumatic diseases, and focus on the management of rheumatic irAEs.</jats:p> Management of immune checkpoint inhibitor‐related rheumatic adverse events Thoracic Cancer |
| spellingShingle | Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Zhang, Wen, Zhang, Li, Thoracic Cancer, Management of immune checkpoint inhibitor‐related rheumatic adverse events, Pulmonary and Respiratory Medicine, Oncology, General Medicine |
| title | Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_full | Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_fullStr | Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_full_unstemmed | Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_short | Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_sort | management of immune checkpoint inhibitor‐related rheumatic adverse events |
| title_unstemmed | Management of immune checkpoint inhibitor‐related rheumatic adverse events |
| topic | Pulmonary and Respiratory Medicine, Oncology, General Medicine |
| url | http://dx.doi.org/10.1111/1759-7714.13249 |